Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
Oliver Bähr, Katharina Filipski, Michael W. Ronellenfitsch, Iris Divé, Joachim P. Steinbach, Marie Therese Forster, Pia S. Zeiner, Patrick N. Harter, Emmanouil Fokas, Marlies Wagner, Eike Steidl
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Classification and treatment of WHO grade II/III gliomas have dramatically changed. Implementing molecular markers into the WHO classification raised discussions about the significance of grading and clinical trials showed overall survival (O
Autor:
Cornelia Becker, Wolfram Pönisch, Maik Schwarz, Markus Scholz, Madlen Jentzsch, Uwe Platzbecker, Andreas Schwarzer, Bruno Holzvogt, Georg-Nikolaus Franke, Uta Schönfelder-Fricke, Juliane Grimm, Leanthe Braunert, Yvonne Remane, Marc Andrea, Thomas Zehrfeld, Sebastian Schwind, Thomas Edelmann, Franz Albert Hoffmann, Tanja Holzhey, Song-Yau Wang, Doreen Hammerschmidt, Markus Bill, Madlen Holzvogt
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Introduction Light chain involvement is observed in almost every patient (pt) with newly diagnosed multiple myeloma (MM). Owing to a relatively short half-life, rapid reduction in the involved free light chain (iFLC) is of potential prognostic value.
Autor:
Céleste Lebbé, Andrew S. Brohl, Meliessa H. Hennessy, Michele Milella, Patrick Terheyden, Kent C. Shih, Paul Nghiem, Isaac Brownell, Gerald P. Linette, Karl D. Lewis, Shailender Bhatia, Murtuza Bharmal, Omid Hamid, Michael Schlichting, Sandra P. D'Angelo, Janice M. Mehnert, Matthias Hunger
Publikováno v:
Cancer Immunology, Immunotherapy
Background Response rates are primary endpoints in many oncology trials; however, correlation with overall survival (OS) is not uniform across cancer types, treatments, or lines of therapy. This study explored the association between objective respon
Autor:
Véronique Bédoucha, Norbert Gattermann, Philipp le Coutre, Prashanth Gopalakrishna, Jerald P. Radich, Weiping Deng, Susanne Saussele, Eibhlin Conneally, Nancy Krunic, Giuseppe Saglio, Andrzej Hellmann, Bruno Martino, Francis J. Giles, Valentín García-Gutiérrez, Tamás Masszi, David M. Ross, María Teresa Gómez Casares, Jesper Stentoft, Andreas Hochhaus
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Ross, D M, Masszi, T, Gómez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, Garcia-Gutierrez, V, Gattermann, N, le Coutre, P D, Martino, B, Saussele, S, Giles, F J, Radich, J P, Saglio, G, Deng, W, Krunic, N, Bédoucha, V, Gopalakrishna, P & Hochhaus, A 2018, ' Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib : 96-week update of the ENESTfreedom study ', Journal of Cancer Research and Clinical Oncology, vol. 144, no. 5, pp. 945-954 . https://doi.org/10.1007/s00432-018-2604-x
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Ross, D M, Masszi, T, Gómez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, Garcia-Gutierrez, V, Gattermann, N, le Coutre, P D, Martino, B, Saussele, S, Giles, F J, Radich, J P, Saglio, G, Deng, W, Krunic, N, Bédoucha, V, Gopalakrishna, P & Hochhaus, A 2018, ' Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib : 96-week update of the ENESTfreedom study ', Journal of Cancer Research and Clinical Oncology, vol. 144, no. 5, pp. 945-954 . https://doi.org/10.1007/s00432-018-2604-x
Purpose: ENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis
Autor:
Mitsuyoshi Utsugi, Reiko Sakurai, Noriaki Sunaga, Akira Mogi, Yoshio Tomizawa, Tomohito Kuwako, Tomomi Masuda, T. Ishizuka, Kyoichi Kaira, Atsushi Takise, Yosuke Miura, Ryusei Saito, Kimihiro Shimizu, Kaori Seki, Koichi Minato, Masanobu Yamada, Hisao Imai, Shinichi Ishihara, Takeshi Hisada
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose In patients with epidermal growth factor receptor (EGFR)-mutated, advanced, non-small cell lung cancer (NSCLC), common gefitinib-sensitive EGFR mutations that predict a greater response to therapy include the exon 19 deletion and L858R point
Autor:
Radoslav Chekerov, Desislava Dimitrova, Jalid Sehouli, Mustafa Zelal Muallem, Ingo B. Runnebaum, Michael P. Lux, Hans Werner Tessen, Oliver Tome, Oumar Camara, Beate Rautenberg, Tanja Trarbach, Gerald Gitsch
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Objective In recurrent ovarian cancer (ROC), there is a high demand on effective therapies with a mild toxicity profile. Treosulfan is an alkylating agent approved as oral (p.o.) and intravenous (i.v.) formulation for the treatment of recurrent ovari
Autor:
Dongjiao Wang, Xiaoyan Zhang, Tian Tian, Jujuan Wang, Hong-Xia Qiu, Qingbo Zhang, Limin Duan, Jianyong Li
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose The significance of positron emission tomography/computed tomography (PET–CT) in identifying patients with lymphoma-associated hemophagocytic lymphohistiocytosis (LAHLH) when pathological evidence is unavailable remains uncertain. Methods I
Autor:
Naoki Nagata, Mutsumi Fukunaga, Hiroshi Kojima, Junichi Sakamoto, Hiroyoshi Takemoto, Toru Kono, Takanori Matsui, Satoshi Morita, Hideyuki Mishima, Yoshinori Munemoto, Taishi Hata, Mitsuo Shimada
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Oxaliplatin-induced peripheral neurotoxicity (OPN) is frequent and potentially severe, but successful treatment of this condition is still an unmet clinical need. We aimed to determine whether treatment with goshajinkigan (TJ-107), a traditio
Autor:
Pingsheng Fan, Gaofei Fan, Kelong Ma, Chengtao Weng, Xianhai Zhu, Qiaohong Duan, Jin Huang, Yabei Liu, Tengyue Zhang
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To assess the clinical efficacy of targeted arterial perfusion of verapamil and chemotherapeutic agents in the interventional therapy of lung cancer. Methods Forty patients with advanced lung cancer underwent treatment with targeted arterial